Literature DB >> 12963125

Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors.

Toru Takano1, Akira Miyauchi, Fumio Matsuzuka, Hiroshi Yoshida, Kanji Kuma, Nobuyuki Amino.   

Abstract

We measured the relative expression levels of galectin-3 mRNA to beta-actin mRNA in normal thyroid tissues, thyroid tumor tissues and thyroid-derived fibroblasts. Galectin-3 mRNA was expressed ubiquitously in both benign and malignant thyroid tumors. Although a significant increase in its expression was observed in papillary carcinomas, no significant difference was observed between follicular carcinomas and adenomas. In contrast to the previous optimistic reports using immunohistochemical analysis of the galectin-3 protein expression, these results demonstrate that galectin-3 mRNA may not be a suitable target for molecular-based diagnosis of thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963125     DOI: 10.1016/s0304-3835(03)00343-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

2.  Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions.

Authors:  Carrie C Lubitz; Stacy K Ugras; J Jacob Kazam; Biaxin Zhu; Theresa Scognamiglio; Yao-Tseng Chen; Thomas J Fahey
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 3.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

4.  Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.

Authors:  Bogdan Galusca; Jean Marc Dumollard; Sandrine Lassandre; Alain Niveleau; Jean Michel Prades; Bruno Estour; Michel Peoc'h
Journal:  Virchows Arch       Date:  2005-05-13       Impact factor: 4.064

5.  BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.

Authors:  Anna Guerra; Vincenzo Marotta; Maurilio Deandrea; Manuela Motta; Paolo Piero Limone; Alessia Caleo; Pio Zeppa; Silvano Esposito; Franco Fulciniti; Mario Vitale
Journal:  Endocrine       Date:  2012-12-01       Impact factor: 3.633

6.  Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.

Authors:  E Saggiorato; S Aversa; D Deandreis; F Arecco; A Mussa; B Puligheddu; S Cappia; S Conticello; M Papotti; F Orlandi
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.